Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

Inclusion Criteria: * Patient is \>= 18 years of age. * Patient has clinical and/or pathological diagnosis of intra-hepatic portal hypertension. * Patient has clinical diagnosis of cirrhosis. * Patient has undergone variceal banding. Exclusion Criteria: * Patient has a Child-Pugh score \>12. * Patient has portal hypertension resulting from hepatic vein obstruction, portal vein occlusion, schistosomiasis, portal vein thrombosis, splenic vein thrombosis, or Budd-Chiari syndrome. * Variceal banding procedure was performed within 1 month of the screening visit. * Patient has active or recurrent variceal bleeding, or has had variceal bleeding within the 12 weeks prior to screening. * Patient is unwilling to discontinue use of vasoactive drugs from the screening visit through the end of the study. * Patient has hepatocellular carcinoma that is being medically treated or is advanced. * Patient has impaired renal function (i.e., serum creatinine concentration \>1.8 mg/dl) * Patient has a history of liver transplant, or is expected to receive a liver transplant during the study period. * Patient has undergone a gastrointestinal or abdominal surgical procedure within 90 days prior to the Screening Visit, or has had a bowel resection at any time.